Analyst firms · HSBC · NVO

HSBC NVO price target and rating history

Novo Nordisk A/S (NVO) · Health Care

HSBC rates Novo Nordisk A/S (NVO) Buy with a $57 price target, as of its latest action on Oct 1, 2025. It has published 3 rating actions on NVO since July 2023, including 1 upgrade and 1 downgrade. Across 4 firms with a NVO price target in the last 12 months, the median target is $41.50.

Current rating

Buy

Price target

$57

Median target, all firms

$41.50

Actions on NVO

3

Every HSBC rating on NVO

• Oct 1, 2025
  UpgradeHSBC upgrades to Buy from Hold
• Jul 31, 2025
  DowngradeHSBC downgrades to Hold from Buy, price target $57
• Jul 14, 2023
  InitiateHSBC starts coverage at Buy

How other firms rate NVO

Each firm's latest rating and stated target in the last 12 months.

Questions about HSBC and NVO

What is HSBC's price target for NVO?

HSBC's latest stated price target for Novo Nordisk A/S (NVO) is $57, from its action on Jul 31, 2025.

What is HSBC's rating on NVO?

HSBC rates NVO Buy, a bullish rating, as of Oct 1, 2025.

When did HSBC last change its view on NVO?

On Oct 1, 2025, HSBC upgrades to Buy from Hold.

How does HSBC's NVO target compare with other analysts?

Across 4 firms with a NVO price target in the last 12 months, the median target is $41.50.

More NVO rating histories

• Morgan Stanley7
• Deutsche Bank4
• Bernstein4
• UBS3

All HSBC ratingsNVO news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.